CVS Health reiterates FY2024 guidance: GAAP EPS ≥$7.06, adjusted ≥$8.30

CVS HEALTH Corp

Reaffirmed FY2024 GAAP diluted EPS guidance of at least $7.06.
Reaffirmed FY2024 Adjusted EPS guidance of at least $8.30.
Reaffirmed FY2024 cash flow from operations guidance of at least $12.0 billion.
CFO Tom Cowhey to discuss business trends at March 5 webcast.
Guidance unchanged; no new financial information provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.